Humulin R

Humulin R is a brand‑name insulin human product supplied as a clear solution for subcutaneous injection. It contains recombinant human insulin as the active ingredient and is marketed in the European Union. The formulation is intended for rapid‑acting glucose control in diabetes management. Humulin R is available only by prescription and is administered by injection under the skin. Patients are advised to rotate injection sites to minimize tissue changes.

Humulin R is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus requiring mealtime insulin. - Type 2 diabetes mellitus when diet, exercise, and oral agents do not achieve target glucose. - Adjunct to basal insulin in a basal‑bolus regimen. - Treatment of gestational diabetes when rapid‑acting insulin is needed.

Like all insulin preparations, Humulin R may cause adverse reactions ranging from mild to severe.

Common: - Hypoglycemia, presenting as sweating, shakiness, or confusion. - Injection‑site pain, redness, or swelling. - Lipodystrophy, including lipohypertrophy at repeated sites. - Transient weight gain due to fluid retention.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Anaphylactic reaction with urticaria, bronchospasm, or angioedema. - Edema or heart failure exacerbation, especially in patients with cardiac disease.

Healthcare providers and patients should observe several precautions when using Humulin R to reduce the risk of complications.

- Monitor blood glucose frequently, especially before meals and at bedtime. - Adjust dose during illness, stress, or changes in physical activity. - Use caution in patients with renal or hepatic impairment. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Educate patients on recognizing and treating hypoglycemia promptly. - Consider pregnancy status; insulin requirements may change during gestation. - Store the product according to manufacturer guidelines to maintain potency.

Humulin R can interact with other medications, affecting glucose control or increasing the risk of adverse events.

Avoid: - Simultaneous administration of additional rapid‑acting insulin products without dose reduction. - High‑dose sulfonylureas that may precipitate severe hypoglycemia.

Use with caution: - Beta‑adrenergic blockers, which can mask hypoglycemia symptoms. - Oral corticosteroids, which may increase insulin resistance and require dose adjustments. - Thiazide diuretics, which can affect potassium levels and glucose metabolism.